论文部分内容阅读
目的:分析乳腺癌复发患者原发灶和复发灶组织中激素受体(HR)、C-erbB-2及P-gp的表达差异及其临床意义。方法:免疫组化方法检测55例乳腺癌原发组织中ER、PR、C-erbB-2及P-gp的表达,并分析其变化情况。结果:原发灶组织中ER、C-erbB-2和P-gp的阳性表达分别为35/55、16/55、35/55,复发灶组织中ER、C-erbB-2和P-gp阳性表达分别为29/55、25/55和50/55,差异有统计学意义,P<0.05;原发灶和复发灶组织中PR表达差异无统计学意义,P>0.05。ER、PR、C-erbB-2和P-gp在原发灶和复发灶之间的变化率分别为54.5%、50.9%、30.9%和18.2%。结论:肿瘤原发灶与复发灶存在异质性,在对乳腺癌复发患者进行临床治疗时,应检测复发灶中分子表达的确切状况。
OBJECTIVE: To analyze the difference of the expression of hormone receptor (HR), C-erbB-2 and P-gp in primary and recurrent tissue of breast cancer recurrence patients and its clinical significance. Methods: The expressions of ER, PR, C-erbB-2 and P-gp in 55 cases of primary breast cancer tissues were detected by immunohistochemistry and their changes were analyzed. Results: The positive expression of ER, C-erbB-2 and P-gp in the primary tumor tissues were 35/55, 16/55 and 35/55, respectively. ER, C-erbB-2 and P-gp The positive expression was 29/55, 25/55 and 50/55, respectively, with significant difference (P <0.05). There was no significant difference in PR expression between the primary and recurrent lesions (P> 0.05). The rates of change of ER, PR, C-erbB-2 and P-gp between primary and recurrent lesions were 54.5%, 50.9%, 30.9% and 18.2%, respectively. Conclusion: There is heterogeneity between primary tumor and recurrent tumor. When the patients with recurrent breast cancer undergo clinical treatment, the exact state of molecular expression in recurrent tumor should be detected.